Ondine Biomedical Inc. OBIMF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 31.75% | 30.78% | 27.03% | 28.33% | 31.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.75% | 30.78% | 27.03% | 28.33% | 31.01% |
| Cost of Revenue | 48.72% | 45.71% | 39.71% | 26.28% | 12.18% |
| Gross Profit | 22.92% | 22.78% | 20.03% | 29.55% | 43.56% |
| SG&A Expenses | -10.62% | -10.51% | -12.40% | 3.13% | 23.53% |
| Depreciation & Amortization | -8.79% | -5.39% | -4.43% | -4.27% | -3.51% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.96% | 45.22% | 49.22% | 52.21% | 57.45% |
| Operating Income | -39.61% | -46.63% | -51.56% | -54.79% | -60.41% |
| Income Before Tax | -39.99% | -47.03% | -51.96% | -55.90% | -62.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.99% | -47.03% | -51.96% | -55.90% | -62.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.99% | -47.03% | -51.96% | -55.90% | -62.49% |
| EBIT | -39.61% | -46.63% | -51.56% | -54.79% | -60.41% |
| EBITDA | -39.75% | -46.78% | -51.73% | -55.01% | -60.92% |
| EPS Basic | 0.42% | 4.34% | 10.14% | 6.11% | 1.46% |
| Normalized Basic EPS | 0.34% | 4.30% | 9.87% | 7.10% | 3.61% |
| EPS Diluted | 0.42% | 4.34% | 10.14% | 6.11% | 1.46% |
| Normalized Diluted EPS | 0.34% | 4.30% | 9.87% | 7.10% | 3.61% |
| Average Basic Shares Outstanding | 37.62% | 51.09% | 69.37% | 69.18% | 68.94% |
| Average Diluted Shares Outstanding | 37.62% | 51.09% | 69.37% | 69.18% | 68.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |